By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tokai Pharmaceuticals 

Boston  Massachusetts    U.S.A.
Phone: Fax:



Company News
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014 11:18:15 AM
Tokai Pharmaceuticals (TKAI) To Ring The Nasdaq Stock Market Opening Bell 11/14/2014 10:18:39 AM
Tokai Pharmaceuticals (TKAI) Reports Third Quarter 2014 Financial Results 11/10/2014 10:19:55 AM
Tokai Pharmaceuticals (TKAI) To Present At Upcoming Healthcare Investor Conferences 11/4/2014 10:19:32 AM
Tokai Pharmaceuticals (TKAI) Announces Closing Of Initial Public Offering 9/24/2014 12:04:40 PM
Tokai Pharmaceuticals Announces Pricing Of Initial Public Offering 9/17/2014 9:19:42 AM
Tokai Pharmaceuticals Bags $97 Million For Prostate Cancer Drug In Upsized IPO 9/17/2014 7:38:06 AM
Tokai Pharmaceuticals Appoints Lee Kalowski As Chief Financial Officer 9/2/2014 11:17:46 AM
Tokai Pharmaceuticals Appoints Daniel T. Dransfield, Ph.D. As Vice President, Head Of Translational Medicine 8/27/2014 8:59:59 AM
Tokai Pharmaceuticals, Chasing The Field In Prostate Cancer, Files For $75 Million IPO 8/12/2014 7:23:11 AM